Agios Pharmaceuticals (AGIO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to -$103.4 million.
- Agios Pharmaceuticals' Income towards Parent Company fell 11091.16% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 16005.72%. This contributed to the annual value of $673.7 million for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Agios Pharmaceuticals' Income towards Parent Company is -$103.4 million, which was down 11091.16% from -$112.5 million recorded in Q2 2025.
- In the past 5 years, Agios Pharmaceuticals' Income towards Parent Company registered a high of $2.0 billion during Q1 2021, and its lowest value of -$112.5 million during Q2 2025.
- Moreover, its 4-year median value for Income towards Parent Company was -$85.4 million (2023), whereas its average is $131.3 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 438287.33% in 2021, then plummeted by 11091.16% in 2025.
- Quarter analysis of 4 years shows Agios Pharmaceuticals' Income towards Parent Company stood at $4.0 million in 2021, then plummeted by 2524.56% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then decreased by 7.16% to -$103.4 million in 2025.
- Its Income towards Parent Company was -$103.4 million in Q3 2025, compared to -$112.5 million in Q2 2025 and -$90.5 million in Q1 2025.